Home/Filings/4/0001104659-21-089435
4//SEC Filing

GRAYZEL DAVID S. 4

Accession 0001104659-21-089435

CIK 0001798749other

Filed

Jul 5, 8:00 PM ET

Accepted

Jul 6, 4:27 PM ET

Size

12.2 KB

Accession

0001104659-21-089435

Insider Transaction Report

Form 4
Period: 2021-07-01
Transactions
  • Purchase

    Common Stock

    2021-07-02$14.00/sh+535,714$7,499,9963,103,879 total(indirect: By Atlas Venture Fund XII, L.P.)
  • Conversion

    Series A Preferred Stock

    2021-07-027,976,7540 total(indirect: By Atlas Venture Fund XII, L.P.)
    Common Stock (2,568,165 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-07-01$11.15/sh+2,153$23,9992,153 total
    Exercise: $19.41Exp: 2031-06-30Common Stock (2,153 underlying)
  • Conversion

    Common Stock

    2021-07-02+2,568,1652,568,165 total(indirect: By Atlas Venture Fund XII, L.P.)
Footnotes (3)
  • [F1]Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
  • [F2]The shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Fund XII"). The general partner of Atlas Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP.. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of the securities held by Atlas Fund XII, except to the extent of his pecuniary interest therein, if any.
  • [F3]This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in two equal installments, with the first installment vesting on September 30, 2021 and the second installment vesting on December 31, 2021.

Issuer

Aerovate Therapeutics, Inc.

CIK 0001798749

Entity typeother

Related Parties

1
  • filerCIK 0001732786

Filing Metadata

Form type
4
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 4:27 PM ET
Size
12.2 KB